Yelena Mostinski

Yelena obtained her Ph.D. degree (direct track) in Medicinal Chemistry from The Hebrew University of Jerusalem in 2018, under the supervision of Prof. Dmitry Tsvelikhovsky. Her doctoral research focused on methodology development for the synthesis of biologically important aliphatic heterocycles and discovery of the new chemical transformations. Following this, she joined the group of Prof. Dr. M. Nazaré as a post-doc. Her research focused on the inhibitors of SHP2 phosphatase (the project was awarded the Minerva Fellowship of the Max-Planck Society) and the development of fluorescent chemical probes for the illumination of cannabinoid receptors. After completing her postdoctoral training, Yelena transitioned to roles in the Israeli biotech industry, serving as a Project and CMC Leader at Galmed Pharmaceuticals (2020-2021) and later as a Senior Medicinal Chemist at FutuRx (2021-2024). In these capacities, she led medicinal and computational chemistry campaigns, as well as overseeing non-clinical ADME and PK/PD activities. In 2024 she re-joined the Nazaré group.